<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150862</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-104</org_study_id>
    <nct_id>NCT03150862</nct_id>
  </id_info>
  <brief_title>A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma</brief_title>
  <official_title>A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, efficacy and clinical activity of BGB-290 in
      combination with radiation therapy (RT) and/or temozolomide (TMZ) in subjects with newly
      diagnosed or recurrent/refractory glioblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open‑label, multiple‑dose, dose-escalation study to determine the safety, pharmacokinetics
      (PK) and pharmacodynamics (PD) of BGB-290 in combination with radiation therapy (RT) and/or
      TMZ with 2 arms and a potential third arm.

      In dose escalation/Phase 1b, BGB-290 will be combined with RT (Arm A) or RT and TMZ (Arm B)
      in subjects with newly diagnosed unmethylated glioblastoma (GB), or BGB-290 will be combined
      with TMZ in subjects with methylated or unmethylated recurrent/refractory GB (Arm C).

      The dose expansion/Phase 2 phase will enroll up to 4 cohorts: subjects with newly diagnosed
      unmethylated GB in Arm A and Arm B, and 2 potential cohorts of subjects with unmethylated and
      methylated recurrent/refractory GB in Arm C. Subjects in dose expansion may continue
      treatment in the absence of safety concerns and disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE</measure>
    <time_frame>From first dose BGB-290 to 10 weeks post-dose (Arms A and B). From first dose BGB-290 to 28 days post-dose (Arm C).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment</measure>
    <time_frame>From first dose BGB-290 to 30 days post dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Arm A [BGB-290 + RT] and Arm B [BGB-290 + RT + TMZ]</measure>
    <time_frame>From first dose BGB-290 to first documentation of progression while subject is alive assessed up to 5 years.</time_frame>
    <description>Modified disease control rate (DCR) using mRANO</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 Arm C [BGB-290 + TMZ]</measure>
    <time_frame>From first dose of BGB-290 to first documentation of progression assessed up to 5 years.</time_frame>
    <description>Objective response rate (ORR) using mRANO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters of BGB-290 of steady state Ctrough</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified disease control rate (DCR). (Arms A and B)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression while subject is alive assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (Arm C)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression while subject is alive assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR).</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR).</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS).</measure>
    <time_frame>From first dose BGB-290 until first documentation of disease progression or death, whichever is first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose BGB-290 until date of death, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR).</measure>
    <time_frame>From the first dose BGB-290 to first documentation of disease progression, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose BGB-290 until first documentation of disease progression or death, whichever is first, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose BGB-290 until date of death, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE</measure>
    <time_frame>From first dose BGB-290 to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dose.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BGB-290 of steady state Ctrough</measure>
    <time_frame>From first dose BGB-290 to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BGB-290 (Cmax)</measure>
    <time_frame>From first dose BGB-290 to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm A and Arm B)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR).</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression while subject is alive, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR).</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose BGB-290 until first documentation of disease progression or death, whichever is first, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose BGB-290 until date of death, assessed up to 5 years</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE</measure>
    <time_frame>From first dose BGB-290 to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment cycles, dose intensity of components of each treatment regimen, and changes in vital signs and clinical laboratory tests during and following treatment</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dose.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BGB-290 of steady state Ctrough</measure>
    <time_frame>From first dose BGB-290 to 30 days post dose.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of BGB-290 (Cmax)</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dose.</time_frame>
    <description>Phase 2 (Arm C)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 18 subjects (newly diagnosed unmethylated GB) to receive BGB-290 and radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 24 subjects (newly diagnosed unmethylated GB) to receive BGB-290, radiation therapy (RT) and temozolomide (TMZ)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 60 subjects (newly diagnosed unmethylated GB) to receive BGB-290 and radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 60 subjects (newly diagnosed unmethylated GB) to receive BGB-290, radiation therapy, and TMZ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 24 subjects with recurrent/refractory methylated or unmethylated GB to receive BGB-290 and TMZ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Dose Expansion-Cohorts C1 and C2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 120 subjects with recurrent/refractory GB (Cohort 1 - 60 subjects with unmethylated GB; Cohort 2 - 60 subjects with methylated GB) to receive BGB-290 and TMZ</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <description>BGB-290</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm A (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm C (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm C (Dose Expansion-Cohorts C1 and C2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMZ</intervention_name>
    <description>TMZ</description>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm C (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm C (Dose Expansion-Cohorts C1 and C2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>Up to 60 Gy (total) over 6 - 7 weeks</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm A (Dose Expansion)</arm_group_label>
    <arm_group_label>Arm B (Dose Expansion)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All subjects

          1. Age ≥ 18 years old.

          2. Confirmed diagnosis of glioblastoma (WHO Grade IV).

          3. Ability to undergo serial MRIs.

          4. ECOG status ≤ 1.

          5. Adequate bone marrow function.

          6. Adequate renal and hepatic function.

          7. Females of childbearing potential and non-sterile males must agree to use highly
             effective methods of birth control throughout the course of study and at least up to
             90 days after last dosing.

          8. Ability to swallow whole capsules.

             Subjects in Arms A and B (not Arm C) must also meet inclusion criteria 8 - 10:

          9. No previous treatment for GB except surgery.

         10. Able to start radiation therapy ≤ 49 days after surgery but ≥ 14 days after a biopsy
             or ≥28 days after an open biopsy or craniotomy with adequate wound healing.

         11. Documented unmethylated MGMT promoter status.

             Subjects in Arm C must also meet inclusion criteria # 12 - 14:

         12. No prior systemic chemotherapy other than TMZ for GB.

         13. Progressive disease &gt; 2 months after completion of first line therapy.

         14. At least one measurable lesion by mRANO.

             Subjects in Arm C Phase 2, Cohort C1 must also meet criteria # 15. This is not
             applicable to subjects enrolled in Arm C, Ph 1b.

         15. Documentation of unmethylated MGMT promoter status.

             Subjects in Arm C Phase 2, Cohort C2 must also meet Criteria #16. This is not
             applicable to subjects enrolled in Arm C Phase 1b.

         16. Documentation of methylated MGMT promoter status.

        Exclusion Criteria: All subjects

          1. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents ≤21 days
             prior to start of study treatment.

          2. Toxicity of ≥ Grade 2 from prior therapy.

          3. Major surgery or significant other injury ≤ 4 weeks prior to start of study treatment.

          4. History of other active malignancies within 2 years with exception of (i) adequately
             treated in situ cancer of the cervix, (ii) non-melanoma skin cancer, or (iii)
             localized adequately treated cancer with curative intent or malignancy diagnosed &gt; 2
             years ago with no evidence of disease and no treatment ≤ 2 years prior to study
             treatment.

          5. Uncontrolled seizure disorder.

          6. Active infection requiring systemic treatment.

          7. Known human immunodeficiency virus (HIV) or active viral hepatitis.

          8. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease,
             ventricular arrhythmia or CVA ≤ 6 months prior to start of treatment.

          9. Active clinically significant gastrointestinal disease.

         10. Active bleeding disorder ≤ 6 months prior to start of treatment.

         11. Need for therapeutic anti-coagulation with heparin, warfarin or other anticoagulants.

         12. Use of any medications or food known to be strong or moderate cytochrome P450, family
             3, subfamily A (CYP3A) inhibitors or strong inducers.

         13. Pregnant or nursing females.

         14. Significant intercurrent illness that may result in subject's death prior to death
             from glioblastoma.

         15. Known hypersensitivity to any component of TMZ or decarbazine (DTIC). [Subjects in
             Arms B and C only.]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katie Wood, MD</last_name>
    <phone>831-218-5309</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rainer Brachmann, PhD</last_name>
    <phone>831-512-1073</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Pazzi, RN, CCRP</last_name>
    </contact>
    <investigator>
      <last_name>Michael Badruddoja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at Health One</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Hannan</last_name>
    </contact>
    <investigator>
      <last_name>Michael Pearlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edwion Nunez</last_name>
    </contact>
    <investigator>
      <last_name>Deborah Forst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Picard</last_name>
    </contact>
    <contact_backup>
      <last_name>Picard</last_name>
    </contact_backup>
    <investigator>
      <last_name>Patrick Wen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pearce</last_name>
    </contact>
    <investigator>
      <last_name>Tobias Walbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Talcott</last_name>
    </contact>
    <investigator>
      <last_name>Jian Campian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Williams</last_name>
    </contact>
    <investigator>
      <last_name>Manmeet Ahluwalia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omar Rasin</last_name>
    </contact>
    <investigator>
      <last_name>Vinay Puduvalli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center (Stephenson Cancer Center)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Williams</last_name>
    </contact>
    <investigator>
      <last_name>James Battiste, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Coxon</last_name>
    </contact>
    <investigator>
      <last_name>Lyndon Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI / Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Hatfield</last_name>
    </contact>
    <investigator>
      <last_name>Kent Shih, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Johnson</last_name>
    </contact>
    <investigator>
      <last_name>Howard Colman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CJ Woodburn</last_name>
    </contact>
    <investigator>
      <last_name>David Schiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult glioblastoma, adult gian cell glioblastoma, adult gliosarcoma, glioma neoplasms</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>neoplasms, central nervous system neoplasms, neoplasms by histologic type, neoplasms by site</keyword>
  <keyword>astrocytoma</keyword>
  <keyword>neuroepithelial</keyword>
  <keyword>neuroectodermal tumors</keyword>
  <keyword>germ cell and embryonal</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>glandular and epithelial</keyword>
  <keyword>nerve tissue, nervous system diseases</keyword>
  <keyword>temozolomide</keyword>
  <keyword>BGB-290</keyword>
  <keyword>alkylating, alkylating agents</keyword>
  <keyword>molecular mechanisms of pharmacological action</keyword>
  <keyword>Poly(ADP-ribose) polymerase inhibitors</keyword>
  <keyword>enzyme inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

